Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.01 EPS

Vistagen Therapeutics (NASDAQ:VTGN) released its quarterly earnings results on Monday. The company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.01, Fidelity Earnings reports.

Vistagen Therapeutics stock opened at $0.54 on Tuesday. Vistagen Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.49. The company has a market capitalization of $25.92 million, a P/E ratio of -0.92 and a beta of 0.31. The firm has a 50 day moving average price of $0.48 and a 200-day moving average price of $0.56.

VTGN has been the subject of several analyst reports. ValuEngine upgraded Vistagen Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Zacks Investment Research raised shares of Vistagen Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Maxim Group reaffirmed a “buy” rating and set a $1.00 target price on shares of Vistagen Therapeutics in a research note on Friday. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $0.85.

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Article: What are trading strategies for the 52-week high/low?

Earnings History for Vistagen Therapeutics (NASDAQ:VTGN)

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply